01
Cardiovascular medicine
- Coronary disease and myocardial infarction
- Ischaemic cardiomyopathy and heart failure
- Peripheral arterial and critical limb ischaemia
- Diabetic vascular disease and microvascular dysfunction
02
Neurology & neuroscience
- Ischaemic and haemorrhagic stroke
- Brain, spinal cord and peripheral nerve injury
- Parkinson’s and Alzheimer’s diseases
- Multiple sclerosis, ALS and neuromuscular disorders
03
Orthopaedics & musculoskeletal medicine
- Osteoarthritis and cartilage defects
- Tendon, ligament, meniscal and rotator cuff injuries
- Bone defects, delayed healing and osteonecrosis
- Sports injury and degenerative spine disorders
04
Metabolic, kidney & liver disease
- Diabetic wounds, neuropathy and nephropathy
- Acute and chronic kidney injury; renal fibrosis
- Acute liver failure, cirrhosis and metabolic liver disease
- Ischaemia–reperfusion and transplant-related injury
05
Lung, skin & wound healing
- ARDS, COPD and pulmonary fibrosis
- Chronic ulcers, pressure injuries and burns
- Surgical, radiation and diabetic wounds
- Complex soft-tissue defects
06
Autoimmune & inflammatory disease
- Systemic lupus erythematosus and systemic sclerosis
- Rheumatoid arthritis
- Crohn’s disease and ulcerative colitis
- Graft-versus-host disease
07
Evidence interpretation
Evidence maturity differs by indication
Clinical readiness must be assessed for a defined product–disease pair. Evidence in one inflammatory disorder does not validate the same cells for cardiac, neurological or orthopaedic disease, because target biology, delivery and endpoints differ.3
The strongest evaluation combines randomised comparison where feasible, validated patient-centred outcomes, transparent adverse-event reporting and follow-up long enough to distinguish transient biological activity from durable benefit.